Literature DB >> 2301421

Drug-use evaluation programs for psychotropic medications.

J D Goad1, J R Ezell.   

Abstract

Drug-use evaluation (DUE) programs for psychotropic medications at a state-operated mental health center are described. DUE programs were developed at Western Missouri Mental Health Center to monitor prescribing of medications in the hospital and ambulatory-care settings. DUE criteria were developed for all major groups of psychotropic medications: antipsychotics, antidepressants, antianxiety and hypnotic agents, lithium, and antiparkinsonian drugs. The criteria appear on special forms developed for the programs; pharmacists use these forms to evaluate every medication order for inpatients and every 50th medication order for ambulatory-care patients. Physicians are alerted to noncompliant prescribing practices by memorandum, oral consultation, or both. In 3204 inpatient DUEs conducted from July 1986 to December 1988, orders for antiparkinsonian drugs showed the poorest compliance with DUE criteria. In both the hospital and ambulatory-care settings, antiparkinsonian agents required the most follow-up. The overall compliance rate for inpatient DUEs was 84%; for ambulatory-care DUEs, the compliance rate was 64%. As a result of the ambulatory-care DUE program, basic laboratory studies and dyskinesia rating scales are being ordered on a more timely basis. These DUE programs have increased pharmacist monitoring of patient care and improved documentation of medication use.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301421

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  6 in total

Review 1.  Impact of drug usage review on drug utilisation.

Authors:  J L Blackburn
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

2.  Sedative-hypnotic use by the elderly: effects on hospital length of stay and costs.

Authors:  E J Yuen; M H Zisselman; D Z Louis; B W Rovner
Journal:  J Ment Health Adm       Date:  1997

3.  Will the new antipsychotics improve the treatment of schizophrenia?

Authors:  T Hale
Journal:  BMJ       Date:  1993-09-25

Review 4.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

5.  A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron.

Authors:  G Dranitsaris; D Warr; A Puodziunas
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

Review 6.  A comprehensive review of the impact of clinical pharmacy services on patient outcomes in mental health.

Authors:  Tom E Richardson; Claire L O'Reilly; Timothy F Chen
Journal:  Int J Clin Pharm       Date:  2013-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.